ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons.ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 7, 2022 | Post-IPO Equity | $60M | — | — | — | Detail |
Mar 24, 2022 | Post-IPO Debt | $150M | 1 | Hayfin Capital Management | — | Detail |
Feb 6, 2020 | Post-IPO Equity | $82.30M | — | — | — | Detail |
May 22, 2019 | Post-IPO Equity | $51.75M | — | — | — | Detail |
Feb 12, 2019 | Post-IPO Debt | $72.50M | 1 | Perceptive Advisors | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hayfin Capital Management | Yes | Post-IPO Debt |
Perceptive Advisors | Yes | Post-IPO Debt |
Marathon Asset Management | Yes | Post-IPO Debt |
Oxford Finance LLC | Yes | Post-IPO Debt |
Burrill & Company | Yes | Series Unknown |
Hercules Capital | — | Post-IPO Debt |
Aisling Capital | — | Series Unknown |
Biomark Capital | — | Series Unknown |
ADMA Biologics has acquired 1 organizations. Their most recent acquisition was Biotest - Therapy business on Jun 6, 2017. They acquired Biotest - Therapy business for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jun 6, 2017
Biotest - Therapy business
|
Biotechnology | acquisition | — | Detail |